BridgeBio Pharma Inc. (NASDAQ: BBIO) will present primary results from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE